Current
Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
MMWR: October 20, 2023 / 72(42);1140–1146
Archived
COVID-19 Vaccination Recommendations and Practices for Women of Reproductive Age by Health Care Providers — Fall DocStyles Survey, United States, 2022
MMWR: September 29, 2023 / 72(39);1045–1051
Archived
Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023
MMWR: June 16, 2023 / 72(24);657–662
Archived
ACIP Interim Recommendations for the Use of Bivalent Booster Doses of COVID-19 Vaccines—United States, October 2022
MMWR, November 11, 2022, 71(45);1436-1441
Archived
ACIP Interim Recommendation for Use of the Novavax COVID-19 Vaccine in Adults 18 years and older — US, July 2022
MMWR, August 5, 2022, 71(31);988–992
Archived
ACIP Interim Recommendations for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022
MMWR Early Release June 28, 2022
Archived
ACIP Recommendation for use of Moderna COVID-19 Vaccine in Adults aged 18 years and older, considerations for extended intervals for primary series doses of mRNA COVID-19 vaccines — US, February 2022
MMWR, March 18, 2022, 71 (11); 416-421
Archived
ACIP Updated Interim Recommendations for Use of the Janssen (Johnson & Johnson) COVID-19 vaccine, US, December 2021
MMWR, January 21, 2022, 71(3);90-95
Archived
ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years - US, 2021
MMWR Early Release, November 5, 2021, 70
Archived
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged 16 Years and older: Recommendations of the Advisory Committee on Immunization Practices — U.S., September 2021
MMWR Early Release, September 21, 2021
Archived
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from ACIP — US, July 2021
MMWR, August 13, 2021, 70(32);1094-1099
Archived
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from ACIP — US, June 2021
MMWR Early Release, July 6, 2021
Archived
ACIP Interim Recommendations for use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 years, US, May 2021
MMWR Early Release, May 14, 2021, 70
Archived
Updated Recommendation from ACIP for Use of Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — U.S. April 2021
MMWR Early Release, April 27, 2021, 70
Archived
ACIP Interim Recommendation for Use of Janssen (Johnson and Johnson) COVID-19 Vaccine - U.S., February 2021
MMWR, March 2, 2021, 70
Archived
ACIP Updated Interim Recommendation for Allocation of COVID-19 Vaccine – U.S., December 2020
MMWR, December 22, 2020, 69
Archived
ACIP Interim Recommendation for Use of Moderna COVID-19 Vaccine – U.S, December 2020
MMWR, December 20, 2020, 69
Archived
ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – U.S., December 2020
MMWR, December 13, 2020, 69
Archived
ACIP Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine – U.S., 2020
MMWR, December 3, 2020, 69
